Somaxon Pharmaceuticals to Report Third Quarter 2012 Results and Conduct Conference Call on Wednesday, October 31
SAN DIEGO, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (SOMX), a specialty pharmaceutical company, today announced that it will release its financial results for the third quarter ended September 30, 2012 on Wednesday, October 31, 2012 after the close of the U.S. financial markets. The Company will also conduct a conference call that same afternoon at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and highlights of the third quarter of 2012.
The conference call will be available to interested parties through a live audio webcast at http://investors.somaxon.com/events.cfm. The webcast will also be archived and accessible at this site for one year. Alternatively, callers may participate in the live conference call by dialing (877) 941-9205 (domestic) or (480) 629-9771 (international), conference call ID 4570871. A telephonic replay will be available for approximately two weeks following the conclusion of the call by dialing (303) 590-3030, and entering passcode 4570871.
About Somaxon Pharmaceuticals, Inc.
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products and late-stage product candidates to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Somaxon's product Silenor, now available by prescription in the United States, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance.
The Somaxon Pharmaceuticals logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13679
For more information, please visit the company's web site at www.somaxon.com .
CONTACT: Tran Nguyen / CFO Somaxon Pharmaceuticals, Inc. (858) 876-6500 Matt Sheldon PondelWilkinson Inc. (310) 279-5975
Source: Somaxon Pharmaceuticals, Inc. 2012 GlobeNewswire, Inc.